The U.S. Food and Drug Administration has expanded its approval for Staar Surgical Company's EVO and EVO+ Visian Implantable Collamer Lenses to include patients aged 21 to 60, up from the previous 21 to 45 age range. The expanded indication is grounded in positive three-year clinical trial data demonstrating sustained safety and efficacy profiles across the broader patient population, potentially opening the market to approximately 8 million additional refractive surgery candidates in the United States.
The approval represents a significant milestone for the Santa Barbara-based medical device manufacturer, as the expanded age eligibility could substantially widen the addressable market for its core lens technology. The EVO and EVO+ lenses are designed to correct myopia and are implanted as an alternative to traditional refractive surgery procedures such as LASIK. The extended indication aligns with growing demand among aging populations seeking vision correction options.
The regulatory clearance comes amid broader expansion in the refractive lens market, where presbyopia-correcting technology has gained increased clinical adoption. The approval may enhance Staar Surgical's competitive positioning within the sector, though market reception will likely depend on clinical adoption rates, reimbursement coverage, and competitive dynamics with alternative vision correction technologies.